Synovus Financial Corp and
Fiera Capital Corp have increased their positions on
Novartis AG, whilst
NewEdge Wealth LLC,
Woodley Farra Manion Portfolio Management Inc.,
Factory Mutual Insurance Co., and
Fifth Third Bancorp acquired shares. Major stakeholders have shown strong support for Novartis, including
HighTower Advisors LLC and
Denali Advisors LLC. This indicates strong market confidence in Novartis’ performance. Novartis' stocks have seen a surge following news of a significant exit from their Indian Unit, with shares increasing by 20%. This comes alongside the licensing deal Novartis secured, worth approximately $1.8 Billion for oral peptide drugs. However, Novartis stocks fell as generics impacted their heart drug sales. Despite potential threats from tariffs, Novartis has protected itself through a U.S. deal. A momentous shift occurred after
Novartis' AG stock reached an all-time high of $160.21 USD. The company continues to show promise, with several analysts closely watching Novartis AG's performance. Concerns arise as
Novartis flags a potential profit drop in 2026 due to the expiry of patents for key drugs.
Novartis Stocks News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 13:42:45 GMT -
Rating 7
- Innovation 2
- Information 7
- Rumor -6
